Literature DB >> 2830675

Alternative mechanisms for activation of human immunodeficiency virus enhancer in T cells.

G J Nabel1, S A Rice, D M Knipe, D Baltimore.   

Abstract

The expression of human immunodeficiency virus (HIV) after T cell activation is regulated by NF-kappa B, an inducible DNA-binding protein that stimulates transcription. Proteins encoded by a variety of DNA viruses are also able to activate expression from the HIV enhancer. To determine how this activation occurs, specific genes from herpes simplex virus type 1 and adenovirus that activate HIV in T lymphoma cells have been identified. The cis-acting regulatory sequences in the HIV enhancer that mediate their effect have also been characterized. The relevant genes are those for ICP0-an immediate-early product of herpes simplex virus type 1-and the form of E1A encoded by the 13S messenger RNA of adenovirus. Activation of HIV by adenovirus E1A was found to depend on the TATA box, whereas herpesvirus ICP0 did not work through a single defined cis-acting element. These findings suggest multiple pathways that can be used to bypass normal cellular activation of HIV, and they raise the possibility that infection by herpes simplex virus or adenovirus may directly contribute to the activation of HIV in acquired immunodeficiency syndrome by mechanisms independent of antigenic stimulation in T cells.

Entities:  

Mesh:

Year:  1988        PMID: 2830675     DOI: 10.1126/science.2830675

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  119 in total

1.  Human immunodeficiency virus type 1 tat protein activates transcription factor NF-kappaB through the cellular interferon-inducible, double-stranded RNA-dependent protein kinase, PKR.

Authors:  F Demarchi; M I Gutierrez; M Giacca
Journal:  J Virol       Date:  1999-08       Impact factor: 5.103

2.  Perturbation of cell cycle progression and cellular gene expression as a function of herpes simplex virus ICP0.

Authors:  W E Hobbs; N A DeLuca
Journal:  J Virol       Date:  1999-10       Impact factor: 5.103

3.  Processing of alpha-globin and ICP0 mRNA in cells infected with herpes simplex virus type 1 ICP27 mutants.

Authors:  K S Ellison; S A Rice; R Verity; J R Smiley
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

Review 4.  Human herpesvirus 6.

Authors:  D K Braun; G Dominguez; P E Pellett
Journal:  Clin Microbiol Rev       Date:  1997-07       Impact factor: 26.132

5.  Epstein-Barr virus latent membrane protein transactivates the human immunodeficiency virus type 1 long terminal repeat through induction of NF-kappa B activity.

Authors:  M L Hammarskjöld; M C Simurda
Journal:  J Virol       Date:  1992-11       Impact factor: 5.103

6.  The human cytomegalovirus 80-kilodalton but not the 72-kilodalton immediate-early protein transactivates heterologous promoters in a TATA box-dependent mechanism and interacts directly with TFIID.

Authors:  C Hagemeier; S Walker; R Caswell; T Kouzarides; J Sinclair
Journal:  J Virol       Date:  1992-07       Impact factor: 5.103

Review 7.  Role of ICP0 in the strategy of conquest of the host cell by herpes simplex virus 1.

Authors:  Ryan Hagglund; Bernard Roizman
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

8.  Activation of the human immunodeficiency virus type 1 long terminal repeat by vaccinia virus.

Authors:  K A Stellrecht; K Sperber; B G Pogo
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

9.  Linker-scanning mutational analysis of the transcriptional activity of the human immunodeficiency virus type 1 long terminal repeat.

Authors:  S L Zeichner; J Y Kim; J C Alwine
Journal:  J Virol       Date:  1991-05       Impact factor: 5.103

10.  Infection with the intracellular protozoan parasite Theileria parva induces constitutively high levels of NF-kappa B in bovine T lymphocytes.

Authors:  V Ivanov; B Stein; I Baumann; D A Dobbelaere; P Herrlich; R O Williams
Journal:  Mol Cell Biol       Date:  1989-11       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.